EFFECTS OF DIFELIKEFALIN ON INFLAMMATORY RESPONSES AND RENAL DYSFUNCTION IN A RAT MODEL OF RENAL ISCHEMIA–REPERFUSION-INDUCED ACUTE KIDNEY INJURY

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/2cf3a3c5bf6693323b94c4c2e9783db8.pdf
EFFECTS OF DIFELIKEFALIN ON INFLAMMATORY RESPONSES AND RENAL DYSFUNCTION IN A RAT MODEL OF RENAL ISCHEMIA–REPERFUSION-INDUCED ACUTE KIDNEY INJURY

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Hiroto
Takeuchi
Hiroto Takeuchi hiroto_takeuchi@pharm.kissei.co.jp Kissei Pharmaceutical Co., Ltd. Central Research Labratory Azumino Japan *
Satoshi Tatemichi satoshi_tatemichi@pharm.kissei.co.jp Kissei Pharmaceutical Co., Ltd. Central Research Labratory Azumino Japan -
Yuji Okuhara yuji_okuhara@pharm.kissei.co.jp Kissei Pharmaceutical Co., Ltd. Safety Research Laboratory Azumino Japan -
Yoshimi Tsukahara yoshimi_tsukahara@pharm.kissei.co.jp Kissei Pharmaceutical Co., Ltd. Safety Research Laboratory Azumino Japan -
Ayaka Yokoyama ayaka_yokoyama@pharm.kissei.co.jp Kissei Pharmaceutical Co., Ltd. Safety Research Laboratory Azumino Japan -
Sumiyoshi Kiguchi sumiyoshi_kiguchi@pharm.kissei.co.jp Kissei Pharmaceutical Co., Ltd. Central Research Labratory Azumino Japan -
Shigeru Nakano shigeru_nakano@pharm.kissei.co.jp Kissei Pharmaceutical Co., Ltd. Central Research Labratory Azumino Japan -
Fumiki Oana fumiki_oana@pharm.kissei.co.jp Kissei Pharmaceutical Co., Ltd. Central Research Labratory Azumino Japan -
Itaru Maruyama itaru_maruyama@pharm.kissei.co.jp Kissei Pharmaceutical Co., Ltd. Central Research Labratory Azumino Japan -
Morimichi Hayashi morimichi_hayashi@pharm.kissei.co.jp Kissei Pharmaceutical Co., Ltd. Safety Research Laboratory Azumino Japan -